Loading company
Tempest Therapeutics, Inc.
TPST · Nasdaq · ·
Next earnings: November 4, 2026
$0.82-3.8%Sep 29 close
- 1M
- -23.0%
- 6M
- -46.3%
- 1Y
- -92.1%
- 5Y
- -99.6%
TPST · Nasdaq · ·
Next earnings: November 4, 2026
$0.82-3.8%Sep 29 close
Tempest Therapeutics, Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending September 30, 2018, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2018 | 3 months toSep 30, 2017 | Change |
|---|---|---|---|
| Total Revenue | $55K | $56K | -1.79% |
| Profit | -$5.2M | -$7.9M | +33.37% |
| Profit per share | -$0.34 | -$2.07 | +83.57% |
| Free Cash Flow | -$2.8M | -$8.4M | +67.04% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We continue to execute against our strategy by advancing our next-generation in vivo CAR-T platform, expanding our expertise with the appointment of two new board members and strengthening our development capabilities through a new collaboration focused on our next-generation in vivo CAR-T candidate, TPST-4003,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Tempest is a clinical-stage biotechnology company pioneering a pipeline of next generation in vivo CAR-T therapies for autoimmune and oncology indications. Tempest’s immune reset technology is embodied in TPST-4003, the company’s lead in vivo CAR-T product candidate, which combines a dual-target CD19/BCMA CAR structure with the company’s proprietary CAR-T delivery platform to support broad B-cell lineage reset across multiple indications. The company’s additional preclinical programs leverage advanced payloads to create a modular in vivo CAR-T portfolio. Tempest envisions a world in which immune reset therapies bring safe, effective, and broadly accessible therapeutic options to patients in need. For additional information, visit Tempest’s website at https://www.tempesttx.com.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Tempest Therapeutics, Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Tempest Therapeutics, Inc. has no earnings call transcript available.